TY - JOUR
T1 - Executive summary of clinical practice guide on fracture risk in lifestyle diseases
AU - from the Japan Osteoporosis Society Lifestyle diseases-related Fracture Risk Investigation Committee
AU - Kanazawa, Ippei
AU - Inaba, Masaaki
AU - Inoue, Daisuke
AU - Uenishi, Kazuhiro
AU - Saito, Mitsuru
AU - Shiraki, Masataka
AU - Suzuki, Atsushi
AU - Takeuchi, Yasuhiro
AU - Hagino, Hiroshi
AU - Fujiwara, Saeko
AU - Sugimoto, Toshitsugu
N1 - Funding Information:
IK has received research grants from MSD, Teijin pharma, and Novartis. MI has received research grants from Chugai Pharmaceutical, Kyowa-Kirin Co, Asahi Kasei Pharma, Ono Pharmaceutical, Novartis Pharma, Bayer Pharmaceutical, Roche DC Japan, Sumitomo Dainippon Pharma, Teijin Pharma, Takeda Pharmaceutical, and lecture and/or consulting fees from Chugai Pharmaceutical, Pfizer Inc, Bayer Pharmaceutical, Kyowa-Kirin Co, Kissei, Torii Pharmaceutical, Daiichi-Sankyo, and Ono Pharmaceutical. DI has received lecture and/or consulting fees from EA Pharma, Astellas Pharma, Asahi Kasei Pharma, Chugai Pharmaceutical, Daiichi-Sankyo Co., Ono Pharmaceutical and Teijin Pharma. MS has received research grants from Chugai Pharmaceutical Asahi Kasei Pharma and lecture fees from Chugai Pharmaceutical Astellas Amgen Biopharma Pfizer Inc Eli Lilly Daiichi-Sankyo Taisho Pharma Teijin Pharma and Asahi Kasei Pharma. MS has received consultant fee from Teijin pharma Co., Asahi Kasei Pharma Co, Daiichi-Sankyo. AS has received research grants from Kowa, Ono Pharmaceutical, Taisho Pharmaceutical, Chugai Pharmaceutical and Takeda Pharmaceutical, as well as lecture and/or consulting fees from Asahi Kasei Pharma, Astellas Pharma, Daiichi-Sankyo, Kyowa Kirin, Taisho Pharmaceutical, Chugai Pharmaceutical and Eli Lilly Japan. YT has received personal fees from Chugai, Daiichi-Sankyo, Teijin Pharma, Asahi Kasei Pharma and Kyowa Kirin. HH has received grants/research support or lecture fees from Asahi Kasei Pharma, Astellas Pharma, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, Mitsubishi Tanabe, Merck Sharp & Dohme, Mochida, Ono, Pfizer, Taisho Toyama Pharmaceutical, and Teijin Pharma. SF has received lecture fees from Teijin, Nippon-Zoki, and Astellas Amgen Japan. TS has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical and Eli Lilly Japan, as well as lecture and/or consulting fees from Asahi Kasei Pharma and Daiichi-Sankyo.
Publisher Copyright:
© 2020, The Japanese Society Bone and Mineral Research and Springer Japan KK, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Accumulating evidence has shown that patients with lifestyle diseases such as type 2 diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease are at increased risk of osteoporotic fracture. Fractures deteriorate quality of life, activities of daily living, and mortality as well as a lifestyle disease. Therefore, preventing fracture is an important issue for those patients. Although the mechanism of the lifestyle diseases-induced bone fragility is still unclear, not only bone mineral density (BMD) reduction but also bone quality deterioration are involved in it. Because fracture predictive ability of BMD and FRAX® is limited, especially for patients with lifestyle diseases, the optimal management strategy should be established. Thus, when the intervention of the lifestyle diseases-induced bone fragility is initiated, the deterioration of bone quality should be taken into account. We here review the association between lifestyle diseases and fracture risk and proposed an algorism of starting anti-osteoporosis drugs for patients with lifestyle diseases.
AB - Accumulating evidence has shown that patients with lifestyle diseases such as type 2 diabetes mellitus, chronic kidney disease, and chronic obstructive pulmonary disease are at increased risk of osteoporotic fracture. Fractures deteriorate quality of life, activities of daily living, and mortality as well as a lifestyle disease. Therefore, preventing fracture is an important issue for those patients. Although the mechanism of the lifestyle diseases-induced bone fragility is still unclear, not only bone mineral density (BMD) reduction but also bone quality deterioration are involved in it. Because fracture predictive ability of BMD and FRAX® is limited, especially for patients with lifestyle diseases, the optimal management strategy should be established. Thus, when the intervention of the lifestyle diseases-induced bone fragility is initiated, the deterioration of bone quality should be taken into account. We here review the association between lifestyle diseases and fracture risk and proposed an algorism of starting anti-osteoporosis drugs for patients with lifestyle diseases.
UR - http://www.scopus.com/inward/record.url?scp=85095567894&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095567894&partnerID=8YFLogxK
U2 - 10.1007/s00774-020-01149-3
DO - 10.1007/s00774-020-01149-3
M3 - Article
C2 - 32892240
AN - SCOPUS:85095567894
VL - 38
SP - 746
EP - 758
JO - Journal of Bone and Mineral Metabolism
JF - Journal of Bone and Mineral Metabolism
SN - 0914-8779
IS - 6
ER -